全球HER2抗體市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計 HER2 抗體市場將從 2025 年的 315.8 億美元成長到 2034 年的 579.1 億美元，2026 年至 2034 年的複合年成長率為 6.97%。

由於HER2陽性癌症（尤其是乳癌和胃癌）的發生率不斷上升，全球HER2抗體市場正經歷顯著成長。 HER2抗體是標靶治療，旨在抑制人類表皮生長因子受體2 (HER2)，HER2在某些癌細胞增殖中起著至關重要的作用。這些治療方法已顯著改善了HER2陽性腫瘤患者的治療效果。

製藥公司正積極研發針對HER2受體的創新單株抗體和抗體藥物複合體。標靶治療和免疫療法的進步正在拓展癌症患者的治療選擇。此外，精準醫療和伴隨診斷的日益普及，也使得醫療服務提供者更容易識別最有可能從HER2標靶治療中獲益的患者。

隨著腫瘤學領域研究的不斷深入，市場預計將持續成長。新型HER2標靶治療和聯合治療方案正在臨床試驗中進行探索。隨著癌症診斷技術的進步和個人化治療策略的普及，全球對HER2抗體的需求將持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球HER2抗體市場：依HER2抗體類型分類

• 市場分析、洞察與預測
• 單株抗體
• 人源化抗體
• 雙特異性抗體
• 奈米抗體

第5章：全球HER2抗體市場：依作用機制分類

• 市場分析、洞察與預測
• HER2抑制
• 免疫調節
• 標靶藥物遞送

第6章：全球HER2抗體市場：依應用領域分類

• 市場分析、洞察與預測
• 乳癌
• 胃癌
• 其他固態腫瘤
• 診斷用途

第7章：全球HER2抗體市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房
• 專業藥品批發商

第8章：全球HER2抗體市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 腫瘤診所
• 研究機構
• 製藥公司

第9章 全球HER2抗體市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Novartis
  • Pfizer
  • Roche
  • Abnova
  • InvivoGen
  • Celltrion
  • Biocon
  • Novus Biologicals
  • Amgen
  • Genentech

The HER2 Antibodies Market size is expected to reach USD 57.91 Billion in 2034 from USD 31.58 Billion (2025) growing at a CAGR of 6.97% during 2026-2034.

The global HER2 antibodies market is experiencing strong growth due to the increasing prevalence of HER2-positive cancers, particularly breast and gastric cancers. HER2 antibodies are targeted therapies designed to block the human epidermal growth factor receptor 2 (HER2), which plays a key role in the growth of certain cancer cells. These therapies have significantly improved treatment outcomes for patients with HER2-positive tumors.

Pharmaceutical companies are actively developing innovative monoclonal antibodies and antibody-drug conjugates targeting HER2 receptors. Advances in targeted therapy and immunotherapy are expanding treatment options for cancer patients. Additionally, the growing adoption of precision medicine and companion diagnostics is helping healthcare providers identify patients who are most likely to benefit from HER2-targeted therapies.

In the future, the market is expected to grow as research in oncology continues to advance. New HER2-targeted therapies and combination treatment approaches are being explored in clinical trials. As cancer diagnosis improves and personalized treatment strategies become more common, the demand for HER2 antibodies will continue to increase globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type of HER2 Antibodies

• Monoclonal Antibodies
• Humanized Antibodies
• Bispecific Antibodies
• Nanobodies

By Mechanism of Action

• HER2 Inhibition
• Immune Modulation
• Targeted Drug Delivery

By Application Areas

• Breast Cancer
• Gastric Cancer
• Other Solid Tumors
• Diagnostic Applications

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Specialty Drug Distributors

By End-User

• Hospitals
• Oncology Clinics
• Research Institutions
• Pharmaceutical Companies

COMPANIES PROFILED

• Novartis, Pfizer, Roche, Abnova, InvivoGen, Celltrion, Biocon, Novus Biologicals, Amgen, Genentech
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HER2 ANTIBODIES MARKET: BY TYPE OF HER2 ANTIBODIES 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type Of Her2 Antibodies
• 4.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Humanized Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Bispecific Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Nanobodies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HER2 ANTIBODIES MARKET: BY MECHANISM OF ACTION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Mechanism Of Action
• 5.2. HER2 Inhibition Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Immune Modulation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Targeted Drug Delivery Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HER2 ANTIBODIES MARKET: BY APPLICATION AREAS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application Areas
• 6.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Gastric Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Solid Tumors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Diagnostic Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HER2 ANTIBODIES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Specialty Drug Distributors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL HER2 ANTIBODIES MARKET: BY END-USER 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End-user
• 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Oncology Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Research Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL HER2 ANTIBODIES MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Type Of Her2 Antibodies
  • 9.2.2 By Mechanism Of Action
  • 9.2.3 By Application Areas
  • 9.2.4 By Distribution Channel
  • 9.2.5 By End-user
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Type Of Her2 Antibodies
  • 9.3.2 By Mechanism Of Action
  • 9.3.3 By Application Areas
  • 9.3.4 By Distribution Channel
  • 9.3.5 By End-user
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Type Of Her2 Antibodies
  • 9.4.2 By Mechanism Of Action
  • 9.4.3 By Application Areas
  • 9.4.4 By Distribution Channel
  • 9.4.5 By End-user
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Type Of Her2 Antibodies
  • 9.5.2 By Mechanism Of Action
  • 9.5.3 By Application Areas
  • 9.5.4 By Distribution Channel
  • 9.5.5 By End-user
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Type Of Her2 Antibodies
  • 9.6.2 By Mechanism Of Action
  • 9.6.3 By Application Areas
  • 9.6.4 By Distribution Channel
  • 9.6.5 By End-user
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL HER2 ANTIBODIES INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Novartis
  • 11.2.2 Pfizer
  • 11.2.3 Roche
  • 11.2.4 Abnova
  • 11.2.5 InvivoGen
  • 11.2.6 Celltrion
  • 11.2.7 Biocon
  • 11.2.8 Novus Biologicals
  • 11.2.9 Amgen
  • 11.2.10 Genentech